



Financial Tear Sheet

Corporate Profile

Incyte's mission is to become one of the leading global oncology companies.

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit the Company's website at www.incyte.com.

Primary IR Contact

Michael Booth, D.Phil.
Vice President, Investor Relations

Phone: 302.498.5914

Fax: 302.425.2707

E-mail: mbooth@incyte.com

Stock Performance

INCY (Common)

| | |
|-------------|-----------------------|
| Exchange | NASDAQ (US Dollar) |
| Price | \$91.92 |
| Change (%) | ▲ 1.61 (1.78%) |
| Volume | 2,059,972 |
| 52 Week Low | \$88.81 |
| Market Cap | \$19,398,549,443 |
| Rolling EPS | -0.76 |
| PE Ratio | N/A |

Shares Outstanding 211,037,309

Data as of January 18, 2018 4:00 p.m. ET



Recent Headlines

January 08, 2018

[Incyte and Syros Announce Global Target Discovery and Validation Collaboration Focused on Myeloproliferative Neoplasms](#)

December 14, 2017

[Incyte to Present at Upcoming Investor Conference](#)

December 10, 2017

[Four-Year Phase 3 Data Analysis Shows Durability of Response of Jakafi® \(ruxolitinib\) in Patients with Polycythemia Vera](#)

Events

There are currently no events scheduled.

Data provided by Nasdaq. Minimum 15 minutes delayed.